Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases

Opus to advance preclinical development programs for BEST1- and RHO-related retinal diseases Opus Genetics, a patient-first, clinical-stage gene therapy company

Related Keywords

United States ,United Kingdom ,Philadelphia ,Pennsylvania ,Belgium ,Heather Anderson ,Ben Yerxa ,Iveric Bio ,Bartp Leroy ,Ghent University Hospital ,Division Of Ophthalmology ,Healthcare Pharmaceuticals Industry ,Raymondg Perelman Center ,Research Triangle Park ,Rd Fund ,Department Of Ophthalmology ,Genetics At Ghent University ,Foundation Fighting Blindnes ,Chief Executive Officer ,Medical Genetics ,Ghent University ,Molecular Therapeutics ,Media Contact ,Genetics Announces Acquisition ,Two Gene Therapy Product Candidates ,Inherited Retinal ,Pharmaceuticals Industry ,Internet News Presswire ,Editorial Guidelines ,Popus ,Genetics ,Announces ,Acquisition ,Of ,The ,Rights ,To ,Two ,Gene ,Therapy ,Product ,Candidates ,For ,Ainherited ,Retinal ,Diseases ,